02/04/2019 GFME actualité 601 |
Page accueil Suite |
Actualité de la recherche scientifique 601
sur les glioblastomes |
|
Actualité 601 du 26/01/2017 Actualité suivante 602 Auteurs : Singh DK1, Kollipara RK2, Vemireddy V3, Yang XL3, Sun Y3, Regmi N3, Klingler S4, Hatanpaa KJ5, Raisanen J5, Cho SK3, Sirasanagandla S6, Nannepaga S3, Piccirillo S7, Mashimo T6, Wang S2, Humphries CG2, Mickey B8, Maher EA9, Zheng H4, Kim RS10, Kittler R11, Bachoo RM12. Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 2- Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 3Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 4Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA. 5Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 6Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 7Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 8Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 9Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 10Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, NY 10461, USA. 11Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: ralf.kittler@utsouthwestern.edu. 12Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: robert.bachoo@utsouthwestern.edu. Les efforts pour identifier et cibler les conducteurs du glioblastome (GBM) se sont concentrés au départ sur les récepteurs tyrosine kinases (RTKs). Mais les avantages cliniques, cependant, ont été insaisissables. Ici, nous identifions le facteur de transcription SRY-related box 2 (SOX2) comme un régulateur indépendant en amont des récepteurs tyrosine kinases RTKs, capable de conduire l'initiation des cellules de gliome. Nous avons identifié le facteur de transcription 2 de l'oligocyte (OLIG2) et ZEB1, Zinc finger E-box binding homeobox 1, lesquels sont fréquemment co-exprimés indépendamment des mutations du conducteur, avec comme cibles SOX2 potentielles. Dans un modèle de gliome murin, nous montrons que des combinaisons différentes antitumorales et des mutations de l'oncogène peuvent activer Sox2, Olig2, et l'expression de Zeb1. Nous démontrons que la co-expression des trois facteurs de transcription peuvent transformer des gènes antitumoraux défectueux chez des astrocytes en cellules initiatrices de gliomes en l'absence, en amont d'oncogènes RTK. Finalement, nous démontrons que la baisse par la mithramycine de l'inhibiteur transcriptionel SOX2 peut entrainer une prolifération réduite des cellules de glioblastome in vivo. MOTS-CLÉ: Le facteur de transcription SRY-related box 2 (SOX2), , Mitramycine, SOX2, Facteur de transcription, Oncogène Pubmed : 28109792 Vocabulaire Mitramycine Antibiotique qui n'est plus utilisé en France. SOX2 Facteur de transcription ZEB2 |
|
Accueil |